Klenil UDV, 800 mcg/2 ml 2 ml 20 pcs

Klenil UDV has anti-inflammatory and anti-allergic effects. It inhibits the release of inflammatory mediators, increases the production of lipomodulin – phospholipase A inhibitor, reduces the release of arachidonic acid, inhibits the synthesis of prostaglandins. It prevents marginal accumulation of neutrophils by reducing inflammatory exudate formation and lymphokine production, inhibits macrophage migration, which leads to slowdown of infiltration and granulation processes.

It increases the number of active a-adrenoreceptors, neutralizes their desensitization, restores the patient’s response to bronchodilators, allowing us to reduce the frequency of their use.

Beclomethasone decreases the number of mast cells in the bronchial mucosa, reduces swelling of the epithelium and mucus secretion by the bronchial glands. Causes relaxation of bronchial smooth muscles, reduces their hyperresponsiveness and improves indices of external respiratory function. It has no mineralocorticoid activity. In therapeutic doses it does not cause side effects typical for systemic GCS. When administered intranasally it eliminates edema and hyperemia of nasal mucosa. Therapeutic effect usually develops after 5-7 days of course of application of beclomethasone. With external and local application it has anti-allergic and anti-inflammatory effects.

Indications

For inhaled use: treatment of bronchial asthma (including when bronchodilators and/or sodium cromoglycate are not effective, as well as hormone-dependent bronchial asthma of severe course in adults and children).

For intranasal use: prevention and treatment of year-round and seasonal allergic rhinitis, including rhinitis in hay fever, vasomotor rhinitis.

For topical and external use: in combination with antimicrobials for infectious inflammatory skin and ear conditions.

Active ingredient

Composition

In 1 ampoule contains:

Beclomethasone dipropionate 800 µg.

Auxiliary substances:

Polysorbate 20,

sorbitan laurate,

sodium chloride,

Purified water.

How to take, the dosage

In adults, when administered by inhalation, the average dose is 400 mcg/day, the frequency of use is 2-4 times/day. If necessary the dose can be increased up to 1 g/day.
For children a single dose is 50-100 mcg/day with 2-4 times a day.

In case of intranasal administration the dose is 400 mcg/day with 1-4 times a day.

When applied topically or topically, the dose depends on the indication and the dosage form used.

Interaction

Concomitant use of beclomethasone with other GCSs for systemic or intranasal use may increase suppression of adrenal cortical function.

Previous inhaled use of beta-adrenergic stimulants may increase the clinical effectiveness of beclomethasone.

Special Instructions

Beclomethasone is not intended to relieve acute asthma attacks. It should also not be used in severe attacks of bronchial asthma requiring intensive therapy. The recommended route of administration for the dosage form used should be strictly observed.

Beclomethasone should be used with extreme caution and under close medical supervision in patients with adrenal insufficiency.

Transfer patients who are always on oral GCS to inhaled forms should only be done when they are stable.

If paradoxical bronchospasm is likely to develop, bronchodilators (e.g., salbutamol) should be inhaled 10-15 minutes before inhaling beclomethasone.

If candidiasis of the oral cavity and upper respiratory tract develops, local antifungal therapy is indicated without stopping treatment with beclomethasone. Infectious inflammatory diseases of the nasal cavity and sinuses are not contraindications to beclomethasone therapy when therapy is indicated.

Inhaled preparations containing 250 mcg beclometasone in 1 dose are not indicated for children under 12 years of age.

Contraindications

– Severe attacks of bronchial asthma requiring intensive therapy.
– Tuberculosis.
– Candidomycosis of the upper respiratory tract.
– First trimester of pregnancy.
– Hypersensitivity to beclomethasone.

Pregnancy use

The use in the second and third trimesters of pregnancy is possible only when the expected benefit to the mother exceeds the potential risk to the fetus. Newborns whose mothers have received beclomethasone during pregnancy should be carefully evaluated for adrenal insufficiency.

If use during lactation is necessary, discontinuation of breastfeeding should be considered.

Similarities